Pace Logo

Life Sciences

Future role of Pace® Life Sciences in supporting biopharmaceutical development and manufacturing coast-to-coast – Dean Bornilla, Vice President.

Life Sciences /

With a growing network of locations across major US pharmaceutical hubs, Pace® aims to enhance customer experience through consistent quality and timely delivery. Pace® Life Sciences, a biopharmaceutical services provider, has experienced significant growth through recent acquisitions of analytical labs, substantially increasing their testing capacity and scientific expertise. Looking ahead to 2025, Pace® is undertaking […]

Future role of Pace® Life Sciences in supporting biopharmaceutical development and manufacturing coast-to-coast – Dean Bornilla, Vice President. Read More »

Pace® Life Sciences Awarded Bronze Medal from EcoVadis for Commitment to Sustainability

Life Sciences /

Company stands out in Ethics, Environment, and Labor and Human Rights focus areas for 2024 Minneapolis, MN – April 1, 2025 –Pace® Life Sciences, LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, is pleased to announce that it has received a Bronze Medal award

Pace® Life Sciences Awarded Bronze Medal from EcoVadis for Commitment to Sustainability Read More »

Pace Life Sciences Frank-Tagliaferri

Addressing the Complexity of Modern Therapeutics – Dr. Frank Tagliaferri, Pace® Life Sciences

Life Sciences /

The modern therapeutic landscape is defined by an ever-growing portfolio of complex drug products – from biologics and gene therapies to mRNA-based vaccines and monoclonal antibodies. These therapies, which often involve intricate fomulations and require advanced sterile processing, have fundamentally altered the demands placed on fill-finish operations. Frank Tagliaferri, chief scientific officer at Pace® Life

Addressing the Complexity of Modern Therapeutics – Dr. Frank Tagliaferri, Pace® Life Sciences Read More »

Pace® Life Sciences to Expand Large Molecule Development, Manufacturing, and Analytical Testing Capacity in 2025

Uncategorized /

Company expands sterile fill-finish services, capacity for biologics development and manufacturing, and more. Minneapolis, MN – January 10, 2025 – Pace® Life Sciences, LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, today announced significant growth plans for two of the company’s locations. Pace® Life

Pace® Life Sciences to Expand Large Molecule Development, Manufacturing, and Analytical Testing Capacity in 2025 Read More »

Pace® Life Sciences Expands Capacity and Capability with Acquisition of Catalent’s Analytical Services Laboratory in Research Triangle Park

Uncategorized /

Company broadens service offerings and strengthens network by purchasing Catalent’s Center-of-Excellence for Small Molecule Analytical Services facility in North Carolina Minneapolis, MN – September [26], 2024 – Pace® Life Sciences, LLC, a contract development, and manufacturing organization (CDMO) and a Division of Pace®, a Science and Technology Company, announced today that it has acquired from

Pace® Life Sciences Expands Capacity and Capability with Acquisition of Catalent’s Analytical Services Laboratory in Research Triangle Park Read More »

Exploring Innovative Means for Biologics Delivery – Dr. Frank Tagliaferri, Pace® Life Sciences

Uncategorized /

Alternative delivery methods for biologics continues to be explored that offer less invasive, less painful administration. Despite their track record of demonstrating significant therapeutic efficacy, biologics still face daunting challenges in their drug delivery. Biologics such as monoclonal antibodies (mAbs) and some vaccines are largely administered via injection or by infusion. These methods can often

Exploring Innovative Means for Biologics Delivery – Dr. Frank Tagliaferri, Pace® Life Sciences Read More »

Pace® Life Sciences Announces Compliant US FDA Inspection of Operations in Oakdale, MN

Uncategorized /

Proven track record of consistent high quality confirmed at Pace® Life Sciences headquarters MINNEAPOLIS, MN., July 25, 2024 (NEWSWIRE.COM): Pace® Life Sciences, a full-service FDA-registered GMP Analytical Testing laboratory and contract development and manufacturing organization (CDMO) and a Division of Pace®, a Science and Technology Company, announced today a successful inspection from The Food &

Pace® Life Sciences Announces Compliant US FDA Inspection of Operations in Oakdale, MN Read More »

Pace® Life Sciences Division Names Dean Bornilla as Head of Commercial

Uncategorized /

Bornilla brings over 25 years of commercial pharmaceutical experience to Pace® MINNEAPOLIS (July 23, 2024) – Pace® Life Sciences, a full-service contract development and manufacturing organization (CDMO) and a Division of Pace®, a Science and Technology Company, announced today that Dean Bornilla has been named Head of Commercial reporting to Dawn Von Rohr, President, Pace® Life

Pace® Life Sciences Division Names Dean Bornilla as Head of Commercial Read More »

Pace® Life Sciences Announces Successful Outcomes Following US FDA Inspection of Operations in San German, Puerto Rico

Uncategorized /

Long-standing reputation for robust quality is confirmed as company enters 2024  SAN GERMAN, PR., March 28, 2024 (NEWSWIRE.COM): Pace® Life Sciences, LLC, a full-service FDA-registered central laboratory and contract development and manufacturing organization (CDMO) announced the receipt of an overall positive review from The Food & Drug Administration (FDA), following a three-day general inspection of

Pace® Life Sciences Announces Successful Outcomes Following US FDA Inspection of Operations in San German, Puerto Rico Read More »